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A great deal of experimental work has been carried out during the past
decade on the influence of androgens on tumours. It was shown (Flaks and Ber,
1938a, 1938b, 1939) that large doses oftestosterone propionate delayed or inhibited
the appearance of skin cancer in mice painted with a 0 3 per cent benzene
solution of methyleholanthrene or benzpyrene. Since these results were pub-
lished, testosterone propionate has been shown to exert an inhibitory influence
on the development of spontaneous mammary tumours in mice (Nathanson and
Andervont, 1939; Lacassagne and Raynaud, 1939; Loeser, 1941 ; Jones, 1941;
Heiman, 1944).
The present experiments were undertaken in order to investigate the influence
of testosterone propionate on subcutaneous tumours.
MATERIAL AND METHODS.
Two hundred and forty-three mice were employed in 8 experiments, in which
varying amounts of the carcinogenic agent and androgen were used. The
number of mice in the experiments had to be limited, owing to the extremely
large doses of testosterone propionate administered. An equal number of mice
served as control in each experiment. Two to four months old mice of mixed
stock (30 females), CBA low cancer strain (110 males and 70 females), C3H (13
males) and Strong A (20 females) high cancer strains, were employed. The CBA
mice were the progeny of females suckled by an Riii mouse 5 to 9 generations
previously. All the females were virgins. Five mice were kept in one box and
fed on rat-cake, wheat, bread and water ad libitum, with an addition of cod liver
oil once a week.
Administration of 20-methylcholanthrene.
On the first day of the experiment all animals received the carcinogenic
agent: 77 control and 76 experimental mice by injection, and 45 control and 45
experimental by implantation of pellets. 0-125 mg., 0-25 mg. and 1D0 mg. of
methyleholanthrene in 0-1-0-25 c.c. of olive oil were injected subcutaneously
near the middle line of the back. The pellets consisted of 5 per cent methylchol-
anthrene in cholesterol (Shear, 1936; Andervont and Shear, 1942), and contained
1.0 mg. of the carcinogen. The diameter of the pellets was 3 mm., the length
7 mm., and weight about 20 mg. The pellets were implanted under ether anaes-
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thesia with a glass trocar. The trocar was introduced under the skin just above
the root of the tail and advanced to the -middle of the back, where the pellets
were deposited. The small wound was closed with a single metal clip. In
experiment 5 the pellets were left permanently under the skin; in experiment
6 they were removed after 8 weeks, and after 4-5 weeks in experiment 7. To
remove the pellet a skin incision was made about 1 cm. from the pellet. In a
number ofcases the removal was easy, but in others a capsule had already formed
around the pellets, and this had to be removed either partially or completely.
Administration of testosterone propionate.
Ninety-five mice received weekly injections of 0-25 c.c. of a 2-5 per cent
solution.of testosterone propionate in arachis oil over a period of 10 to 12 weeks.
The first injection was given simultaneously with methylcholanthrene except in
experiment 8, in which the injections started 2 weeks previous to the adminis-
tration of the carcinogen. The total dose was 50.0 to 75 0 mg. in 2-5 to 3 0 c.c.
ofarachis oil. The injections were made under the skin ofthe abdomen, and were
remote from those of the carcinogenic agent which was given on the back. The
first injections were made in the region of both groins until there was no more
space available, while successive injections were given at different points over
the whole abdominal area. It was difficult to introduce 2-5 to 3-0 c.c. of the oily
solution during the 10 to 12 weeks without losing a part of the solution. The
loss of testosterone propionate was minimized by advancing the needle to the
opposite side of the abdomen before injecting.
Twenty-six mice were implanted with 2 to 4 tablets oftestosterone propionate
under the skin of the abdomen on the day of administration of the carcinogenic
agent. The tablets were implanted by means of a trocar in the same manner as
the methylcholanthrene-cholesterol pellets.
Control mice.
In the experiments in which the mice were injected with testosterone pro-
pionate the controls were given pure arachis oil in amounts equal to those con-
taining the testosterone propionate and at the same sites and intervals. In the
experiments in which the mice received tablets of testosterone the controls were
given no control tablets.
The appearance of tumours was recorded at weekly intervals. Palpation of
the skin in the region of the injection or implantation of the carcinogenic agent
was helpful in detecting the earliest tumours, which were preceded by some
thickening and lack of mobility of the skin in this area. Only nodules which
grew during the succeeding period of observation were recorded as tumours.
Mice bearing tumours were kept until they died. Sixty of the induced tumours
were fixed in 10 per cent formalin for histological examination.
RESULTS.
A. Mlice injected with methylcholanthrene.
Experiment 1 (1-0 mg. of methylcholanthrene, 62-5 mg. of testosterone pro-
pionate; 10 control and 10 treated mice):-The first tumour appeared at 10
weeks in the control and at 15 weeks from the beginning ofthe experiment in the
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treated mice (Table I). At the end of 14 weeks 8 tumours were present in the
control, and none in the treated group. The last two control mice died with
tumours 19 weeks from the start of the experiment; two of the treated mice
TABLE I.-Experiment 1: Development of Subcutaneous Tumours in CBA Mice
Injected with 1 my. of 20-methylcholanthrene in Olive Oil. Ten Treated Mice
Received 62-5 mg. of Testosterone Propionate during the First 10 Weeks of the
Experiment.
Week.
Xi
tu
8 .
9
10
11
12
13
14
15
16
17
18
19
10 control mice. 10 treated mice.
Living. Dead. Living. Dead.
Tithout With Without With Without With Without With
smour. tumour. tumour. tumour. tumour. tumour. tumour. tumour.
10 0. 0 0.10 0. 0 0
10 0 . 0. 10 0 . 0 0
9 1 0 0 .10 0 . 0 0
5 5 . 0 0 .10 0 . 0 0
5 5 . 0 0 .10 0 . 0 0
3 7 . 0 0 .10 0 . 0 0
2 8 . 0 0 .10 0 . 0 0
0 9 . 0 1 . 7 3 0 0
0 7 . 0 3 . 5 5 . 0 0
0 4 . 0 6 . 3 6 0 1
0 2 0 8 . 3 6 . 0 1
o 0 . 0 10 . 3 5 . 0 2
....... 1 5 0 4 ....... . 0 6 0 4
....... 0 3 0 7
....... . 0 3 . 0 7 ....... . 0 2 0 8
....... 0 2 0 8
... .. . 0 0 . 0 10
Total
tumouirs.
Control. Treated.
0 0
* 0 0
* 1 0
* 5 ~0
5 0
7 0
8 0
. 10 3
* .- .0
... 7
. .. 7
. .. 7
* .. 9
10
with tumours survived for 26 weeks. The average latent period was 12 weeks
in the control and 17 weeks in the treated group. The average time of survival
from the beginning ofthe experiment was 16 and 21 weeks respectively. During
10 weeks of treatment the average increase in weight of the control mice was
5 g. and ofthe treated mice 6 g.
*S e
I CBA c. 10
'2+ c tr. 10
2 CBA c. 20
e tr. 20
& CaH c. 7
tr. 6
4 CBA c. 10
- tr. 10
5* Stock c. 15
tr. 15
6t A c. 10
9 tr. 10
7t CBA c. 20
7+e tr. 20
Methylcholanthrene. Testosterone
- , A . propionate.
Injected. Implanted.
I ,I r- Inj. Impl.
Conc. Mg. Cone. Mg. mg. mg.
0o4% 1-0 - - 62-5
0-1% 0-25 - -
0-1%
0-05%
0-25
0-125
5%
5%
5%
1-0
1.0
1-0
75 0
75 0
7560
75-01
60-0
40-0
TABLE II.-Sumnmary of Experiments 1 to 7 on the: Influence (
Tumours al
Numerator = mice with tumow
8.
0/i
1/0
9.
2/0
0/1
0/1
i o
10.
1/0
1/1
6/1
11.
4/0
o
. .:
12.
4/0
1/4
6/5
2/0
0/1
6/4
13.
2/0
./.
1/0
1/0
./.
0/1
14.
1/0
*1./ 1/1
0/1
1/0
. .
3/0
2/0
15.
2/0
3/0
0/2
0/2
i o
i O
0/1
1/b
2/0
16. 17. 18. 19. 20. 21.
2/0
1/0
1/0
i/0
i.o
1/0
0/1
i o 1,/0
2/0
3/0
5/0
1/i
.io
1/0
1/0
2/0
1/0
-1/0
1/0
3/0
i o 1,/0
i o
i/i
1/0
. .
210
22.
ilo
i*l
Abbreviations employed: c. = contrc
* The implanted hydrocarbon-cholesterol pellets were 12
to 5 weeks. § Mice dying before the first tumour occurr
with 75*0 mg. of testosterone propionate.
20
21
-22
23
24
25
26
r-
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Experiment 2 (0-25 mg. of methylcholanthrene, 75-0 mg. of testosterone pro-
pionate; 20 control and 20 treated mice) :-The first tumour appeared in the
control mice after 9 weeks, and in the treated after 13 weeks (Table II). At
the end of 12 weeks 6 tumours were present in the control and none in the treated
group. After 15 weeks 3 control and 4 treated mice died without tumours.
After 24 weeks 15 tumours developed in the control and 10 tumours in the treated
mice.
Experiment 3 (0.25 mg. of methylcholanthrene, 60-0 mg. of testosterone pro-
pionate; 7 control and 6 treated mice):-The first tumour was observed in the
control after 8 weeks, and after 16 weeks in the treated mice (Table II). Two
control mice died without tumours early in the experiment. At the end of 15
weeks 4 tumours were present in the control and none in the treated group.
After 20 weeks all control mice died with tumours, while 2 tumours developed
in the treated group. The 6 treated mice died within 22 weeks, 2 of them with
tumiours.
Experiment 4 (0-025 mg. of methylcholanthrene, 75-0 mg. of testosterone pro-
pionate; 10 control and 10 treated mice):-During the 12th week of the experi-
ment 5 mice suddenly died in the treated group. The first tumour appeared
after 9 weeks in the control as compared with 16 weeks in the treated mice (Table
1I). After 14 weeks 3 control mice developed tumours, while none appeared in
the treated mice. After 28 weeks 6 tumours occurred in the control mice and
3 tumours in the treated mice.
Experiment 8 (1-0 mg. of methylcholanthrene, 50-0 mg. of testosterone pro-
pionate; 30 control and 30 treated mice, 15 of each sex):-Injections of testo-
sterone propionate were started 2 weeks before the administration of the car-
cinogen. All the mice were killed after 13 weeks and their tumours recorded.
Tin cases where small nodules were present their nature was established by
histological examination.
It is shown in Table IV that after 13 weeks .9 tumours were present in the
14 surviving control females (64 per cent), while an equal number of treated
Testosterone Propionate on the Induction of Subcutaneous Tumours.-)a
deaths withiout tunmours in weeks.
Denominator = iie Iyinig withouit tumnours.
23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 4 .44.0
0 10 10 10 10.8
0 10 10 l5 15-4
2 19 15 9 11.6 1/0.1I'0 I. . 1,0.1/0 .. 3 19 13 13 15-7
0 7 94
"O ~~~~~~~~~~~~~~0 5 2 16 16.0 1/0 . 10."i,o 10 .0IO .. 0 1(1 10 9 14-6
~~~ ~~~~~o ~~ 1/0 1/0..1 5 4 16 17-5 1/0 I io l"O' ]Jo~~~~~~~~~~~1, . . 0 13 1., 14 16-2 1/0 1/0.01 . .i, o~ .0 13 1(1 17 17-6 1/0 . . . 10 ..010 9 7 11 12-4
io
i 0/1 ....2 8 4 14 13-0 ~~/o i/o 1~~0. .. 10 .. 0/3 01l 7 20 9 14 15*2 10"' 1,0 0'2 . .. 01 02 . . . 1 16 10 14 14-8
tr. treatedI coiie. conceentration.
permnanently. f Remioved after 8 weeks. IRemoved after- 4
are excluided. Teni miice were implanited and 10 injected
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females developed only 3 tumours (21 per cent). The male mice did not show a,
clear-cut result. Five treated males died early without tumours. The surviving
10 males showed 4 tumours, while 15 control males developed 7 tumours. This
difference is not statistically significant.
The total nuniber of tumours in males and females was 16 out of 29 control
mice (55.1 per cent) and 7 out of 24 treated mice (29.1 per cent)-a statistically
significant difference.
B. Mice implanted uith methylcholanthrene-cholesterol pellets.
Experiment 5 (P10 mg. of methylcholanthrene, pellets left permanently;
75 0 mg. of testosterone propionate; 15 control and 15 treated mice):-The
first tumour appeared after 14 weeks in the control and after 17 weeks in the
treated mice. Three treated mice died without tumours between the 15th and
19th week (Table II). At the end of 16 weeks 5 tumours were present in the
control and none in the treated group. After 32 weeks 14 control mice and 9
treated mice developed tumours. The average increase in weight of testo-
sterone-treated mice during the first 8 weeks of treatment was the same as in the
control mice. At the end of 15 weeks, however, a slight decrease in both control
and treated mice occurred.
Experiment 6 (1 0 mg. of methylcholanthrene, pellets removed after 8 weeks;
40 0 mg. of testosterone propionate; 10 control and 10 treated mice): The first
tumour arose after 11 weeks in the control, and after 14 weeks in the treated
inice (Table II). At the end of 13 weeks 3 tumours were found in the control
and none in the treated group. Two control and 3 treated mice died early
without tumours. After 36 weeks there were 7 tumours in the control and 4
tumours in the treated group.
Experiment 7 (1P0 mg. of methylcholanthrene, pellets removed after 4-S
weeks ; 62-5-75i0 mg. of testosterone propionate ; 20 control and 20 treated
mice) :- In both groups the first tumour developed after 14 weeks (Table II). At
the end of 20 weeks 4 tumours were present in the control and 7 tumours in the
treated mice. After 28weeks 8 tumours occurred in the control, while 10 tumours
were present in the treated group. This result differs from the results of all
the other experiments (see p. 391).
The injection of testosterone propionate over a period of 10 to 12 weeks
(Experiments 1, 2 and 4) or the implantation of approximately the same amount
of the hormone (Experiments 2 and 3) delayed the appearance of subcutaneous
tumours in mice receiving the carcinogen by about 4-5 weeks. No effect of
testosterone propionate was observed in experiments in which the carcinogen
was implanted in pellets and later removed.
The amount ofhormone absorbed from the injected oily solution is not known.
The amount absorbed from the implanted tablets was calculated from the initial
weight of the tablets and the weight after removal on the death of the host.
The rate of absorption was about 4 mg. per month. In mice surviving for more
than 5 months the tablets were almost completely absorbed.
Sixty tumours were examined histologically. Fifty-six were sarcomata (93.3
per cent) and 4 skin carcinomata (6.7 per cent).
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DISCUSSION.
In Experiment 1, in which 1.0 mg. of the carcinogenic agent was employed, all
the control and treated mice died with tumours. This shows that testosterone
had only a delaying influence, and was unable to prevent the carcinogenic action
of methylcholanthrene.
In Experiments 2 to 4, in which smaller doses of methylcholanthrene were
injected (025 mg. and 0*125 mg.), testosterone propionate caused not only delay
in tumourappearance, butalso alowertumourincidence after 24weeks. Twenty-
six tumours developed in 36 control mice (72.2 per cent) and 14 tumours in 29
treated mice (48-2 per cent)-a statistically significant result.
In Experiments 5 to 7, 10 mg. of methylcholanthrene was implanted in 5 per
cent hydrocarbon-cholesterol pellets. This method was at first considered to
be more precise, because it was thought that the carcinogenic agent would be
absorbed in uniform amounts over a given period. However, a comparison of
the tumour incidence after injections and pellet implantations showed that the
tumours did not occur earlier or at more regular intervals with the latter method.
In Experiment 6 the pellets were removed after 8 weeks, and in Experiment 7
after 4 to 5 weeks. In some mice the pellets were encapsulated in varying
degrees, and the removalofthe capsule in a number ofmice could not be avoided.
This is likely to have influenced the tumour incidence, and thus to have made a
comparison between control and treated mice unreliable. Therefore, the results
of Experiments 6 and 7 may be open to criticism. In these experiments no effect
of testosterone propionate was observed. This was in contrast with thie experi-
ments in which methylcholanthrene was injected in olive oil. No adequate
explanation can be given at present. However, the findings of the experiments
on the induction of sarcomata in mice implanted with methylcholanthrene-
cholesterol pellets by Shimkin and Wyman (1947) may be of interest. They
implanted 0002 to 0-5 mg. of methylcholanthrene in a 0 1 to 25 per cent con-
centration in cholesterol into C3H male mice. No shortening ofthe latent period
was observed when higher concentrations and doses were implanted. The
authors suppose that the localization of the hydrocarbon by means of choles-
terol may have removed the differences in the latent period, as compared with
that of the mice given the carcinogen in tricaprylin.
In the present experiments, in which 5 per cent hydrocarbon-cholesterol
pellets were implanted and remained permanently under the skin, the latent
period and the tumour incidence were similar to those in which mice were injected
with the carcinogenic agent in much lower concentrations (0 4 to 0.1 per cent).
However, when the pellets were removed after a short exposure (4 to 5 weeks)
the latent period was longer and the incidence of tumours lower than in mice
injected with lower concentrations of the carcinogen. This may have altered
the results of testosterone treatment, because the bulk of the androgen was
injected long before the tumours began to develop. The unequal removal of the
carcinogenic agent in individual control and treated mice may also have been
responsible for the negative result, because mice treated with testosterone were
not discarded, even ifit was felt that a small part of the carcinogenic pellet mav
have been left.
The need for larger groups of animals in experiments in which the influence
on the latent period or on the incidence of tumours is investigated was fully
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realized. In the present experiments the large doses of testosterone propionate
employed (about 8-0 g. of the hormone in all) precluded the use of larger groups
of animals. Owing to the rather small number of mice employed in Experiments
1 to 7 the number of tumours induced in the control and experimental mice at
4-weekly intervals in each ofthe experiments was added and the tumour incidence
compared (Table III). This was considered admissible, as the dose of the car-
TABLE III.-Experiments 1 to 7: Total Incidence of Tumours.
Control. Treated.
Weeks. Effectivet Number of Per cent of Effectivel Number of Percenit of
total mice. tuniours. tumours. total mice. tumours. tuinours.
12 90 . 19 21* 1 80 . 0 0
16 90 38 . 42-2* 76 17 22-3*
20 90 50 55-5t 76 . 39 51-3±
* This difference is statistically significant.
t This difference is not significant.
t Mice dying before the first tumour occurred are excluded.
cinogen was the same in both groups of each experiment and the dose of testo-
sterone propionate was almost uniform (62.5 to 75-0 mg.).
The following results were obtained when the numbers of tumours in the
control and treated mice occurring at 4-weekly intervals were compared. Up to
the end of 12 weeks from the beginning ofthe experiments the results were clear-
cut. There were no tumours inthe 80 treated mice, and 19 tumours were observed
in 88 control mice alive at that time. Between the 12th and 16th week the
tumours began toappearin thetreatedmice. Attheendofthis period 38tumours
were found in the control (42-2 per cent) as compared with 17 tumours in the
treated mice (22-3 per cent). Thus, although there were twice as many tumours
in the control as in the experimental mice, approximately the same number of
new tumours developed in both groups during these 4 weeks. Between the 16th
and 20th week 12 new tumours appeared in the control and 22 in the treated
mice. The total number of tumours reached 50 in the control and 39 in the
treated mice.
A significant difference in the influence of testosterone propionate on the
development of tumours in males and females was observed in Experiment 8
(Table IV).
TABLE IV.-Experiment 8: Incidence of Tumours after 13 Weeks.
Number of
Sex. Number of Effectivet tumours and Per cent of mice. total mice. deaths without tumours.
tumours.*
Y Control 15 14 9/1 64
Treated 15 14 . 3/1 21
Control 15 15 7/0 46
Treated 15 10 4/5 40
* Numerator mrice with tumours. Denominator mice dead without tumours.
t Mice dying before the first tumour cccurred are excluded.
The massive doses of testosterone propionate employed did not cause any loss
of weight in the treated mice. On the contrary, a slight increase in weight of
the treated in comparison with the control mice was observed. Testosterone
propionate exerted a marked influence on male and female genital organs:
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hypertrophy of the seminal vesicles in the male, enlargement of the uterus and
vagina, hypertrophy of the clitoris and an extreme hypertrophy of the clitoral
glands in the female. Atrophy ofthe thymus and adrenals was the most striking
finding in both sexes. Enlargement of the kidneys was also encountered. In
addition, marked pigmentation of the mammary nipples in all dark-coated
females (Flaks, 1948) and prolapse of the vagina and uterus in a number of mice
was observed.
No connection could be found, at the present stage ofthe experiments, between
the delaying influence of testosterone on carcinogenesis and the well-defined
changes induced by the hormone in many organs. The hyperpigmentation of
the nipples, which seems to be an outcome of increased activity of oxidation
processes induced by testosterone propionate in the tissues, and indicated by the
formation of black melanin, may prove to be of help in the understanding of the
effect of testosterone on tumours.
The mechanism of the interference of testosterone with the action of methyl-
cholanthrene is not known. Some workers consider the inhibitory influence of
testosterone on spontaneous mammary tumours in mice as a castration effect.
According to these workers, testosterone, byinhibitingtheproduction ofoestrogen
in the ovaries inhibits the development of the mammary glands. They claim
that this effect is similar to that first obtained by Lathrop and Loeb (1916), and
Cori (1927), who showed that castration offemale mice, at an early age, inhibited
the development of breast cancer. The present experiments, in which an in-
hibitory influence on subcutaneous tumours induced by methylcholanthrene
was only obtained after large doses of testosterone, suggest that this influence
may not be hormonal. Doses which gave hormonal effects, such as masculiniza-
tion, were not sufficient to produce even slight inhibition of tumours (Flaks and
Ber, 1938a, 1938b). It is possible, therefore, that testosterone may directly
interfere, at least temporarily, with the malignant transformation of the normal
cell under the influence of methylcholanthrene.
SUMMARY.
1. The influence of large doses of testosterone propionate (50 0-75-0 mg.) on
the latent period and the incidence of subcutaneous tumours induced by 20-
methylcholanthrene in 121 mice ofseveral strains was investigated. One hundred
and twenty-two mice served as controls.
2. An average delay of about 4 weeks in the appearance of 50 per cent of
subcutaneous tumours induced by methvlcholanthrene was observed after 62-5-
75 0 mg. of testosterone propionate injected over a period of 10-12 weeks.
3. This result confirms and extends the findings of previous experiments in
which the influence oftestosterone propionate on skin cancer induced by painting
with methylcholanthrene was studied.
4. The total incidence oftumours in mice treated with testosterone propionate
was significantly reduced only up to the 16th week after the administration of
the carcinogen (42-2 per cent to 22-3 per cent). No significant difference was
observed later.
5. Implantation of testosterone propionate exerted a similar influence.
6. There was no decrease in weight of mice after large doses of testosterone
propionate.
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7. Testosterone propionate produced masciulinization and hyperpigmentation
of the mammary nipples in female mice. A few mice developed prolapse of the
vagina and uterus.
8. The nature of the delaying influence of testosterone propionate on tumour
induction remains to be elucidated.
9. Histological examination of 60 of the induced tumours revealed 56 sar-
comata (93.3 per cent) and 4 squamous-celled carcinomata (6.7 per cent).
The author is indebted for the generous gift of " Testoviron " to Dr. R. L.
Walsh and Mr. T. E. Riddle of British Schering Ltd., and to Dr. W. A. R.
Thomson, of Boots Pure Drug Co., Ltd., for the testosterone propionate tablets.
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